ClavystBio — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses such as influenza and COVID at the nasal mucosa to prevent initial infection and transmission.
BiotechDeep TechHealthtechLeiden, NL
Koenraad Wiedhaup(Founder & Chief Executive Officer)inRonald Brus(Founder & Chief Growth Officer)inJaap Goudsmit(Founding Scientist and Senior Advisor)inDinko Valerio(Founder and Chair of the Supervisory Board)Jintanat Ananworanich(Chief Medical Officer)Clarissa Koch(Chief Scientific Officer)
Co-investorsF-Prime CapitalGV (Google Ventures)Bluebird VenturesCasdin CapitalEuropean Innovation Council FundEuropean Investment Bank+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.